Planned Versus Provisional Use of Glycoprotein IIb/IIIa Inhibitors in Smokers Undergoing Percutaneous Coronary Intervention

American Journal of Cardiology

Volumn 97, Issue 12, 2006, Pages 1679-1684

  Robertson, Jason O ^a   Lincoff, A Michael ^a   Wolski, Kathy ^a   Topol, Eric J ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECEPTOR BLOCKING; STABLE ANGINA PECTORIS; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 33744541294     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2005.12.066     Document Type: Article

References (30)

1. Wilhelmsen L. Coronary heart disease. epidemiology of smoking and intervention studies of smoking. Am Heart J 115 (1988) 242-249
2. Kannel W.B. Update on the role of cigarette smoking in coronary artery disease. Am Heart J 101 (1981) 319-328
3. Kannel W., McGee D.L., and Castelli W.P. Latest perspectives on cigarette smoking and cardiovascular disease. the Framingham Study. J Cardiac Rehabil 4 (1984) 267-277
4. Celermajer D.S., Sorensen K.E., Georgakopoulos D., Bull C., Thomas O., Robinson J., and Deanfield J.E. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88 (1993) 2149-2155
5. Kiowski W., Linder L., Stoschitzky K., Pfisterer M., Burckhardt D., Burkart F., and Buhler F.R. Diminished vascular response to inhibition of endothelium-derived nitric oxide and enhanced vasoconstriction to exogenously administered endothelin-1 in clinically healthy smokers. Circulation 90 (1994) 27-34
6. Zeiher A.M., Schachinger V., and Minners J. Long-term cigarette smoking impairs endothelium-dependent coronary arterial vasodilator function. Circulation 92 (1995) 1094-1100
7. Fuster V., Chesebro J.H., Frye R.L., and Elveback L.R. Platelet survival and the development of coronary artery disease in the young adult. effects of cigarette smoking, strong family history and medical therapy. Circulation 63 (1981) 546-551
8. Zwaal R.F., Comfurius P., and Bevers E.M. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1180 (1992) 1-8
9. Meade T.W., Vickers M.V., Thompson S.G., Stirling Y., Haines A.P., and Miller G.J. Epidemiological characteristics of platelet aggregability. Br Med J (Clin Res Ed) 290 (1985) 428-432
10. Folts J.D., and Bonebrake F.C. The effects of cigarette smoke and nicotine on platelet thrombus formation in stenosed dog coronary arteries. inhibition with phentolamine. Circulation 65 (1982) 465-470
11. Wilhelmsen L., Svardsudd K., Korsan-Bengtsen K., Larsson B., Welin L., and Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 311 (1984) 501-505
12. Kimura S., Nishinaga M., Ozawa T., and Shimada K. Thrombin generation as an acute effect of cigarette smoking. Am Heart J 128 (1994) 7-11
13. Hioki H., Aoki N., Kawano K., Homori M., Hasumura Y., Yasumura T., Maki A., Yoshino H., Yanagisawa A., and Ishikawa K. Acute effects of cigarette smoking on platelet-dependent thrombin generation. Eur Heart J 22 (2001) 56-61
14. McGill Jr. H.C. The cardiovascular pathology of smoking. Am Heart J 115 (1988) 250-257
15. Kelly T.L., Gilpin E., Ahnve S., Henning H., and Ross Jr. J. Smoking status at the time of acute myocardial infarction and subsequent prognosis. Am Heart J 110 (1985) 535-541
16. Grines C.L., Topol E.J., O'Neill W.W., George B.S., Kereiakes D., Phillips H.R., Leimberger J.D., Woodlief L.H., and Califf R.M. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation 91 (1995) 298-303
17. Barbash G.I., White H.D., Modan M., Diaz R., Hampton J.R., Heikkila J., Kristinsson A., Moulopoulos S., Paolasso E.A., Van der Werf T., et al. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation 87 (1993) 53-58
18. Gomez M.A., Karagounis L.A., Allen A., Anderson J.L., and TEAM-2 Investigators. Effect of cigarette smoking on coronary patency after thrombolytic therapy for myocardial infarction. Second Multicenter Thrombolytic Trials of Eminase in Acute Myocardial Infarction. Am J Cardiol 72 (1993) 373-378
19. Lee K.L., Woodlief L.H., Topol E.J., Weaver W.D., Betriu A., Col J., Simoons M., Aylward P., Van de Werf F., Califf R.M., and GUSTO-I Investigators. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation 91 (1995) 1659-1668
20. de Chillou C., Riff P., Sadoul N., Ethevenot G., Feldmann L., Isaaz K., Simon J.P., Boursier M., Khalife K., Thisse J.Y., and Aliot E. Influence of cigarette smoking on rate of reopening of the infarct-related coronary artery after myocardial infarction. a multivariate analysis. J Am Coll Cardiol 27 (1996) 1662-1668
21. Ishihara M., Sato H., Tateishi H., Kawagoe T., Shimatani Y., Kurisu S., Sakai K., and Ueda K. Clinical implications of cigarette smoking in acute myocardial infarction. acute angiographic findings and long-term prognosis. Am Heart J 134 (1997) 955-960
22. Hasdai D., Lerman A., Rihal C.S., Criger D.A., Garratt K.N., Betriu A., White H.D., Topol E.J., Granger C.B., Ellis S.G., et al. Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. Am Heart J 137 (1999) 612-620
23. Mueller H.S., Cohen L.S., Braunwald E., Forman S., Feit F., Ross A., Schweiger M., Cabin H., Davison R., Miller D., et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis In Myocardial Infarction (TIMI) trial, phase II. Circulation 85 (1992) 1254-1264
24. Lincoff A.M., Bittl J.A., Harrington R.A., Feit F., Kleiman N.S., Jackman J.D., Sarembock I.J., Cohen D.J., Spriggs D., Ebrahimi R., et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA 289 (2003) 853-863
25. Lincoff A.M., Bittl J.A., Kleiman N.S., Sarembock I.J., Jackman J.D., Mehta S., Tannenbaum M.A., Niederman A.L., Bachinsky W.B., Tift-Mann III J., et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93 (2004) 1092-1096
26. Cohen D.J., Lincoff A.M., Lavelle T.A., Chen H.L., Bakhai A., Berezin R.H., Jackman D., Sarembock I.J., and Topol E.J. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention. results from the REPLACE-2 trial. J Am Coll Cardiol 44 (2004) 1792-1800
27. Moliterno D.J., Willard J.E., Lange R.A., Negus B.H., Boehrer J.D., Glamann D.B., Landau C., Rossen J.D., Winniford M.D., and Hillis L.D. Coronary-artery vasoconstriction induced by cocaine, cigarette smoking, or both. N Engl J Med 330 (1994) 454-459
28. Maroo A., and Lincoff A.M. Bivalirudin in PCI. an overview of the REPLACE-2 trial. Semin Thromb Hemost 30 (2004) 329-336
29. Caron M.F., and McKendall G.R. Bivalirudin in percutaneous coronary intervention. Am J Health Syst Pharm 60 (2003) 1841-1849
30. Cho L., Bhatt D.L., Wolski K., Lincoff M., Topol E.J., and Moliterno D.J. Effect of smoking status and abciximab use on outcome after percutaneous coronary revascularization. pooled analysis from EPIC, EPILOG, and EPISTENT. Am Heart J 141 (2001) 599-602